Shrinkage of a lactotroph macroadenoma in response to dopamine agonist treatment

Shrinkage of a lactotroph adenoma in response to treatment with the dopamine agonist cabergoline as shown by post-gadolinium magnetic resonance imaging. A 37-year-old male presented with headaches and was found to have an enormous sellar mass (A, arrow) and a prolactin level of 7248 ng/mL. He was treated with cabergoline, and after 2 months, the prolactin had decreased to 745 ng/mL and the size of the mass had decreased markedly (B, arrow). After 12 months of cabergoline treatment, the prolactin had decreased to 9.2 ng/mL and the mass had decreased even further (C, arrow).